Skip to main content
Premium Trial:

Request an Annual Quote

After the Sequence

At the Loom, Carl Zimmer bemoans what he dubs the "Yet-Another-Genome Syndrome." Sequencing a genome, he writes, used to be different — it took forever to do and was a big deal when it came out — but with next-generation sequencing, it takes comparatively no time at all, yet they still generate tons of press releases and news articles. It's what comes after the sequencing, Zimmer says, that is interesting. "What remains truly exciting is the kind of research starts after the genomes are sequenced: discovering what genes do, mapping out the networks in which genes cooperate, and reconstructing the deep history of life," he writes, adding that "insights like these are newsworthy. The sequencing of those genomes, on its own, is not."

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.